Trellis Bioscience

The immune system is the most powerful weapon in nature against diseases. Trellis Bioscience, a biotechnology company funded by the NIH and venture capital, leverages its proprietary CellSpot™ technology to obtain rare, naturally optimized antibodies from healthy donor blood to combat infectious diseases and cancer. Trellis Bioscience has developed a technology platform for cellular informatics, and the company’s technology can be used for the discovery and production of therapeutic monoclonal antibodies.